Keyword: Orchard Therapeutics
Armed with a total of $375 million raised, Orchard will build its own manufacturing site in California, to start running in 2021.
Orchard Therapeutics priced its IPO at $14 a share, raising $200 million and exceeding the $173 million goal it set earlier this month.
DFCI's Haining to become VP, Oncology at Merck; Pfizer poaches Quest exec to spearhead digital; and Perrigo swaps CEO for former tobacco executive.
The offering will give the GlaxoSmithKline-backed biotech the means to take three gene therapies through the clinic and onto the market.
The series C continues a transformative year defined by the acquisition of GSK's portfolio of approved and experimental rare disease gene therapies.
CAR-T maker Cell Medica names Kite’s European chief as CEO; Oncorus poaches a Moderna cancer executive; and Achaogen axes R&D and its C-suite.